Open AccessHydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features
Author(s) -
Anna L. Godfrey,
Peter J. Campbell,
Cathy MacLean,
Georgina Buck,
Julia Cook,
Julie Temple,
Bridget S. Wilkins,
Keith Wheatley,
Jyoti Nangalia,
Jacob Grinfeld,
Mary Frances McMullin,
Cecily Forsyth,
JeanJacques Kiladjian,
Anthony Green,
Claire Harrison
Publication year - 2018
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2018.78.8414
Subject(s) - medicine , essential thrombocythemia , aspirin , thrombocytosis , thrombosis , hydroxycarbamide , surgery , anagrelide , clinical endpoint , randomized controlled trial , polycythemia vera , platelet , chemotherapy
Cytoreductive therapy is beneficial in patients with essential thrombocythemia (ET) at high risk of thrombosis. However, its value in those lacking high-risk features remains unknown. This open-label, randomized trial compared hydroxycarbamide plus aspirin with aspirin alone in patients with ET age 40 to 59 years and without high-risk factors or extreme thrombocytosis.